亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study

医学 内科学 队列 临床终点 T790米 无进展生存期 人口 肿瘤科 置信区间 临床试验 癌症 化疗 表皮生长因子受体 吉非替尼 环境卫生
作者
Shun Lü,Yiping Zhang,Guojun Zhang,Jianying Zhou,Shundong Cang,Ying Cheng,Gang Wu,Peiguo Cao,Dongqing Lv,Hong Jian,Chengshui Chen,Xiangming Jin,Panwen Tian,Kai Wang,Guanming Jiang,Gongyan Chen,Qun Chen,Hui Zhao,Cuimin Ding,Renhua Guo
出处
期刊:Journal of Thoracic Oncology [Elsevier BV]
卷期号:17 (10): 1192-1204 被引量:27
标识
DOI:10.1016/j.jtho.2022.06.002
摘要

INTRODUCTION: Befotertinib (D-0316) is a novel, third-generation EGFR tyrosine kinase inhibitor (TKI). This study evaluated befotertinib in patients with locally advanced or metastatic NSCLC who developed an EGFR T790M mutation after progression on first- or second-generation EGFR TKI therapy. METHODS: This was a single-arm, open-label, phase 2 study at 49 hospitals across mainland China. Patients with locally advanced or metastatic NSCLC harboring EGFR T790M mutations with disease progression after prior first- or second-generation EGFR TKI therapy received oral befotertinib of 50 mg (cohort A) or 75 to 100 mg (cohort B) once daily. The primary end point was objective response rate (ORR) assessed by an independent review committee in intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT03861156. RESULTS: A total of 176 patients and 290 patients were included in cohorts A (50 mg) and B (75-100 mg), respectively. At data cutoff (August 15, 2021), independent review committee-assessed ORR was 67.6% (95% confidence interval [CI]: 61.9%-72.9%) in cohort B. The investigator-assessed ORR was 54.0% (95% CI: 46.3%-61.5%) in cohort A and 65.9% (95% CI: 60.1%-71.3%) in cohort B. The median investigator-assessed progression-free survival was 11.0 (95% CI: 9.6-12.5) months in cohort A and 12.5 (95% CI: 11.1-13.8) months in cohort B. The median independent review committee-assessed progression-free survival in cohort B was 16.6 (95% CI: 15.0-not evaluable [NE]) months. The intracranial ORR was 26.7% (95% CI: 7.8%-55.1%) in cohort A by investigator assessment, while 57.1% (95% CI: 34.0%-78.2%) and 55.9% (95% CI: 37.9%-72.8%) in cohort B by investigator and independent review committee assessment, respectively. The median investigator-assessed intracranial progression-free survival was 16.5 (95% CI: 8.6-NE) months in cohort A, while the median intracranial progression-free survival was not evaluable in cohort B due to immature data regardless of investigator or independent review committee assessment. and NE (95% CI: 13.8-NE) in cohort B. The overall survival was immature. Grade 3 or higher treatment-related adverse events and treatment-related serious adverse events occurred in 20.5% and 11.4% of patients in cohort A and in 29.3% and 10.0% of patients in cohort B, respectively. CONCLUSIONS: Befotertinib of 75 to 100 mg has satisfying efficacy and manageable toxicity in patients with locally advanced or metastatic NSCLC harboring T790M mutation with resistance to first- or second-generation EGFR TKIs. A phase 3 randomized trial is underway (NCT04206072).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
14秒前
如意大神完成签到,获得积分10
15秒前
19秒前
寒冷的月亮完成签到 ,获得积分10
22秒前
23秒前
落后的雪青完成签到,获得积分10
35秒前
39秒前
44秒前
YYY发布了新的文献求助10
45秒前
Maestro_S的应助被Heaven采纳,获得10
46秒前
46秒前
MT完成签到,获得积分10
54秒前
光亮的成败完成签到,获得积分10
54秒前
55秒前
快乐夜阑完成签到,获得积分10
58秒前
完美世界的应助被Heaven采纳,获得10
58秒前
1分钟前
Shicheng完成签到,获得积分10
1分钟前
zhiwei完成签到,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
腼腆的乘云完成签到,获得积分10
1分钟前
Ttimer发布了新的文献求助10
1分钟前
自觉康乃馨完成签到,获得积分10
1分钟前
ZYP完成签到,获得积分10
1分钟前
受伤若男完成签到,获得积分10
2分钟前
2分钟前
拉长的映波完成签到,获得积分10
2分钟前
yoshi发布了新的文献求助10
2分钟前
2分钟前
yoshi完成签到,获得积分10
2分钟前
搜集达人的应助被yoshi采纳,获得10
2分钟前
2分钟前
公冶愚志完成签到 ,获得积分10
3分钟前
3分钟前
失眠晟睿完成签到,获得积分10
3分钟前
平淡的忆梅完成签到,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179920
求助须知:如何正确求助?哪些是违规求助? 9570103
关于积分的说明 21808354
捐赠科研通 7775701
什么是DOI,文献DOI怎么找? 3433193
关于科研通互助平台的介绍 2557347
邀请新用户注册赠送积分活动 2478918